Intended for healthcare professionals

Letters Ranibizumab and bevacizumab

Prescribing bevacizumab off-label contravenes GMC advice

BMJ 2011; 343 doi: (Published 08 November 2011) Cite this as: BMJ 2011;343:d7131
  1. Graham Kyle, consultant ophthalmologist1
  1. 1Liverpool L1 9AR, UK
  1. grahamkyle33{at}

Jackson and Kirkpatrick recommend adopting cheaper bevacizumab over more expensive ranibizumab to treat wet age related macular degeneration.1 However, their cost projections “do not consider any potential differences in safety, medicolegal risk, treatment burden, or patient preference . . . .”

The medicolegal risks of such an adoption are considerable, not least for …

View Full Text

Log in

Log in through your institution


* For online subscription